Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Emond

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Toxicology Mechanisms and Methods|December 22, 2009
A physiological pharmacokinetic model based on tissue lipid content for simulating inhalation pharmacokinetics of highly lipophilic volatile organic chemicalsClaude Emond, Kannan Krishnan
Archives of Toxicology|February 5, 2022
Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessmentsClaude Emond, Luc Multigner
Journal of Toxicology and Environmental Health. Part A|July 13, 2005
Physiologically based modeling of the accumulation in plasma and tissue lipids of a mixture of PCB congeners in female Sprague-Dawley ratsClaude Emond, Michel Charbonneau, Kannan Krishnan
Toxicology and Applied Pharmacology|December 14, 2016
Physiologically based pharmacokinetic toolkit to evaluate environmental exposures: Applications of the dioxin model to study real life exposuresClaude Emond, Patricia Ruiz, Moiz Mumtaz
Toxicological Sciences : an Official Journal of the Society of Toxicology|April 2, 2004
Physiologically based pharmacokinetic model for developmental exposures to TCDD in the ratClaude Emond, Linda S Birnbaum, Michael J DeVito
Toxicology and Applied Pharmacology|August 14, 2021
A PBPK model describing the pharmacokinetics of γ-HBCD exposure in miceClaude Emond, Michael J DeVito, Linda S Birnbaum
Archives of Toxicology|January 23, 2025
A physiologically based pharmacokinetic (PBPK) model describing the kinetics of a commercial mixture α-, β-, and γ-hexabromocyclododecane exposure in miceClaude Emond, Michael J DeVito, Linda S Birnbaum
Environmental Health Perspectives|September 13, 2006
Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDDClaude Emond, Linda S Birnbaum, Michael J DeVito
Journal of Applied Toxicology : JAT|May 9, 2025
Toxicological Response of the BEAS-2B Cell After Acute Exposure at the Air-Liquid Interface to Ethylbenzene and m-Xylene Alone and in Binary MixturesNour Jaber, Claude Emond, Fabrice Cazier, et al.
International Journal of Nanomedicine|March 2, 2016
Toward a general physiologically-based pharmacokinetic model for intravenously injected nanoparticlesUlrika Carlander, Dingsheng Li, Olivier Jolliet, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Toxicology Mechanisms and Methods|December 22, 2009
A physiological pharmacokinetic model based on tissue lipid content for simulating inhalation pharmacokinetics of highly lipophilic volatile organic chemicalsClaude Emond, Kannan Krishnan
Archives of Toxicology|February 5, 2022
Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessmentsClaude Emond, Luc Multigner
Journal of Toxicology and Environmental Health. Part A|July 13, 2005
Physiologically based modeling of the accumulation in plasma and tissue lipids of a mixture of PCB congeners in female Sprague-Dawley ratsClaude Emond, Michel Charbonneau, Kannan Krishnan
Toxicology and Applied Pharmacology|December 14, 2016
Physiologically based pharmacokinetic toolkit to evaluate environmental exposures: Applications of the dioxin model to study real life exposuresClaude Emond, Patricia Ruiz, Moiz Mumtaz
Toxicological Sciences : an Official Journal of the Society of Toxicology|April 2, 2004
Physiologically based pharmacokinetic model for developmental exposures to TCDD in the ratClaude Emond, Linda S Birnbaum, Michael J DeVito
Toxicology and Applied Pharmacology|August 14, 2021
A PBPK model describing the pharmacokinetics of γ-HBCD exposure in miceClaude Emond, Michael J DeVito, Linda S Birnbaum
Archives of Toxicology|January 23, 2025
A physiologically based pharmacokinetic (PBPK) model describing the kinetics of a commercial mixture α-, β-, and γ-hexabromocyclododecane exposure in miceClaude Emond, Michael J DeVito, Linda S Birnbaum
Environmental Health Perspectives|September 13, 2006
Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDDClaude Emond, Linda S Birnbaum, Michael J DeVito
Journal of Applied Toxicology : JAT|May 9, 2025
Toxicological Response of the BEAS-2B Cell After Acute Exposure at the Air-Liquid Interface to Ethylbenzene and m-Xylene Alone and in Binary MixturesNour Jaber, Claude Emond, Fabrice Cazier, et al.
International Journal of Nanomedicine|March 2, 2016
Toward a general physiologically-based pharmacokinetic model for intravenously injected nanoparticlesUlrika Carlander, Dingsheng Li, Olivier Jolliet, et al.
Pageof 4